A new study in the UK will investigate the long-term effects of lung inflammation and scarring from COVID-19, Imperial College London announced on Wednesday.
After battling COVID-19, many patients experience long-term symptoms of lung damage, including breathlessness, coughing, fatigue and limited ability to exercise.
The inflammation in the lungs may improve over time, but in some people it persists and in severe cases the lungs may become scarred, Imperial explained.
Supported by GBP2m of funding from UK Research and Innovation (UKRI), the researchers at Imperial aim to develop treatment strategies to prevent the development of severe scarring and disability following COVID-19.
(USD1=GBP0.73)
Immunic granted European patent for vidofludimus calcium dosing regimens
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Kelun-Biotech and Harbour BioMed receive China IND approval for atopic dermatitis therapy
Melodia Therapeutics reports award of US patent covering MLD-151
GSK to acquire 35Pharma for USD950m to strengthen cardiopulmonary pipeline
Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH
Formosa Pharmaceuticals signs licensing deal with Arrotex for APP13007 in Australia and New Zealand
Merck and Mayo Clinic launch AI-driven drug discovery collaboration
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
Hoth Therapeutics granted US patent for novel exon-skipping therapy targeting allergic diseases
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval
Devonian reports gene expression data showing Thykamine's molecular effects in MASH model
Arctic Therapeutics enrols first patients in Phase IIa trial of AT-004 for acne vulgaris